Edwards Lifesciences Corporation (EW): Price and Financial Metrics
Edwards Lifesciences Corporation (EW)
Today's Latest Price: $71.69 USD
Updated Oct 30 7:00pm
Add EW to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
EW Stock Summary
- EW has a higher market value than 95.74% of US stocks; more precisely, its current market capitalization is $44,680,668,691.
- With a one year PEG ratio of 1,800.09, Edwards Lifesciences Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.94% of US stocks.
- In terms of volatility of its share price, EW is more volatile than 93.07% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Edwards Lifesciences Corp, a group of peers worth examining would be PHG, ATVI, BSX, ILMN, and TEL.
- EW's SEC filings can be seen here. And to visit Edwards Lifesciences Corp's official web site, go to www.edwards.com.
EW Stock Price Chart Interactive Chart >
EW Price/Volume Stats
| Current price | $71.69 | 52-week high | $87.79 |
| Prev. close | $72.91 | 52-week low | $51.51 |
| Day low | $70.92 | Volume | 3,131,454 |
| Day high | $72.81 | Avg. volume | 3,635,580 |
| 50-day MA | $81.22 | Dividend yield | N/A |
| 200-day MA | $74.28 | Market Cap | 44.68B |
Edwards Lifesciences Corporation (EW) Company Bio
Edwards Lifesciences provides products and technologies to treat structural heart disease and critically ill patients worldwide. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company was founded in 1999 and is based in Irvine, California.
EW Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $71.69 | $6.38 | -91% |
Below please find a table outlining a discounted cash flow forecast for EW, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Edwards Lifesciences Corp ranked in the 10th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Edwards Lifesciences Corp, consider:
- In the past 5.68 years, Edwards Lifesciences Corp has a compound free cash flow growth rate of -0.05%; that's higher than only 15.04% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 7.08% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- EW's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.72% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -91% |
| 1% | -91% |
| 2% | -91% |
| 3% | -91% |
| 4% | -91% |
| 5% | -91% |
VAR, BLFS, COO, LGND, and RGEN can be thought of as valuation peers to EW, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...